Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of apremilast in moderate to severe plaque psoriasis
2010-019991-55Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Apremilast 30 mg BID with Placebo (2 arms). Primary endpoint: PASI-75 response at Week 16. Started Sep 2010; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2010-019991-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019991-55.